Presented By: Biomedical Engineering
BME 500 Seminar: Nicholas A. Graham, Ph.D.
“Systems biology approaches to drug discovery for cancer and aging”
Nicholas A. Graham, Ph.D.
Mork Family Department of Chemical Engineering and Materials Science,
University of Southern California
“Systems biology approaches to drug discovery for cancer and aging”
Abstract:
“Omics” technologies have enabled network-level measurements of genes, proteins, and metabolites from cellular models of disease. Systems biology attempts to synthesize these quantitative measurements into data-driven models to explain biological function and identify targeted therapeutic drugs. Here, I will discuss three different engineering systems biology approaches using metabolomics, proteomics, and bioinformatics to identify or discover drugs for cancer and aging. First, using metabolomics, we designed a synergistic drug combination that mimics nutrient deprivation to kill cancer cells. Second, by integrating a proteomic signature of cellular senescence with large-scale drug screening databases, we predicted and then validated that EGFR inhibitors are toxic to a model of cellular aging, specifically senescent human mammary epithelial cells. Finally, we developed a bioinformatic approach to integrate gene expression data with drug screening data from hundreds of cancer cell lines to identify clinically approved drugs whose efficacy depends on metabolic pathway activity. Taken together, these studies demonstrate how metabolomics, proteomics, and bioinformatics can all serve to identify drugs for cancer and aging.
Mork Family Department of Chemical Engineering and Materials Science,
University of Southern California
“Systems biology approaches to drug discovery for cancer and aging”
Abstract:
“Omics” technologies have enabled network-level measurements of genes, proteins, and metabolites from cellular models of disease. Systems biology attempts to synthesize these quantitative measurements into data-driven models to explain biological function and identify targeted therapeutic drugs. Here, I will discuss three different engineering systems biology approaches using metabolomics, proteomics, and bioinformatics to identify or discover drugs for cancer and aging. First, using metabolomics, we designed a synergistic drug combination that mimics nutrient deprivation to kill cancer cells. Second, by integrating a proteomic signature of cellular senescence with large-scale drug screening databases, we predicted and then validated that EGFR inhibitors are toxic to a model of cellular aging, specifically senescent human mammary epithelial cells. Finally, we developed a bioinformatic approach to integrate gene expression data with drug screening data from hundreds of cancer cell lines to identify clinically approved drugs whose efficacy depends on metabolic pathway activity. Taken together, these studies demonstrate how metabolomics, proteomics, and bioinformatics can all serve to identify drugs for cancer and aging.
Livestream Information
ZoomSeptember 16, 2021 (Thursday) 4:00pm
Meeting ID: 97723483179
Explore Similar Events
-
Loading Similar Events...